Mavyret, a treatment for hepatitis C, has a list price of approximately $1,000 per pill, with a full treatment course costing around $71,400 [1]. However, the actual out-of-pocket cost for patients can vary significantly due to insurance coverage, patient assistance programs, and pharmacy discounts [1].
¿Cuánto cuesta un tratamiento completo de Mavyret?
A complete treatment course of Mavyret, typically lasting eight weeks, is priced at about $71,400 based on its per-pill cost of $1,000 [1].
¿Qué factores influyen en el precio final de Mavyret para los pacientes?
The final cost for patients can be influenced by several factors. Insurance plans often have different tiers of coverage for prescription drugs, affecting the copay or coinsurance required. Manufacturer-sponsored patient assistance programs and coupons can reduce out-of-pocket expenses for eligible individuals [1]. Additionally, pharmacies may offer their own discounts or be part of networks that negotiate lower prices.
¿Existen programas de asistencia para reducir el costo de Mavyret?
Yes, there are patient assistance programs available that can help lower the cost of Mavyret. These programs are often run by the drug manufacturer and may provide financial assistance to eligible patients who meet certain income or insurance criteria [1].
¿Cómo se compara el costo de Mavyret con otros tratamientos para la hepatitis C?
The cost of Mavyret is comparable to other direct-acting antiviral (DAA) medications for hepatitis C, which generally have high price tags. While the list prices are substantial, many newer hepatitis C treatments offer high cure rates, which can lead to long-term cost savings by preventing the progression of liver disease and its associated complications [1].
¿Cuándo expira la patente de Mavyret?
Information regarding the specific patent expiry dates for Mavyret is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [2]. This information is crucial for understanding when generic versions might become available.
¿Pueden los genéricos de Mavyret estar disponibles antes de la expiración de la patente?
Generally, generic versions of drugs cannot be legally marketed until patent and exclusivity protections expire. However, patent litigation can sometimes lead to earlier market entry for generics if patents are successfully challenged or invalidated [2].